Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graciela Cross

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Clinical Nuclear Medicine|July 8, 2014
Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancerFabián Pitoia, Fernanda Bueno, Graciela Cross
Endocrine|September 23, 2016
Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSHFabian Pitoia, Erika Abelleira, Graciela Cross
European Thyroid Journal|March 12, 2015
Recombinant human thyroid-stimulating hormone-aided remnant ablation achieves a response to treatment comparable to that with thyroid hormone withdrawal in patients with clinically relevant lymph node metastasesFabián Pitoia, Erika Abelleira, Graciela Cross
Archives of Endocrinology and Metabolism|September 3, 2015
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndromeFabián Pitoia, Fernanda Bueno, Angélica Schmidt, et al.
Archives of Endocrinology and Metabolism|September 3, 2015
Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancerFabián Pitoia, Erika Abelleira, Fernando Jerkovich, et al.
Arquivos Brasileiros De Endocrinologia E Metabologia|June 10, 2011
Patients with familial non-medullary thyroid cancer have an outcome similar to that of patients with sporadic papillary thyroid tumorsFabián Pitoia, Graciela Cross, María E Salvai, et al.
European Thyroid Journal|August 9, 2017
Should Age at Diagnosis Be Included as an Additional Variable in the Risk of Recurrence Classification System in Patients with Differentiated Thyroid CancerFabián Pitoia, Fernando Jerkovich, Anabella Smulever, et al.
Thyroid : Official Journal of the American Thyroid Association|March 23, 2013
Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systemsFabián Pitoia, Fernanda Bueno, Carolina Urciuoli, et al.
Medicina|May 27, 2008
Sex hormone binding globulin decrease as a potential pathogenetic factor for hirsutism in adolescent girlsGraciela Cross, Karina Danilowicz, Martha Kral, et al.
Medicina|October 28, 2014
[Female hyperandrogenemia and normal serum levels of testosterone and sex hormone binding globulin]Karina Danilowicz, Oscar D Bruno, Daniela Mana, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Clinical Nuclear Medicine|July 8, 2014
Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancerFabián Pitoia, Fernanda Bueno, Graciela Cross
Endocrine|September 23, 2016
Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSHFabian Pitoia, Erika Abelleira, Graciela Cross
European Thyroid Journal|March 12, 2015
Recombinant human thyroid-stimulating hormone-aided remnant ablation achieves a response to treatment comparable to that with thyroid hormone withdrawal in patients with clinically relevant lymph node metastasesFabián Pitoia, Erika Abelleira, Graciela Cross
Archives of Endocrinology and Metabolism|September 3, 2015
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndromeFabián Pitoia, Fernanda Bueno, Angélica Schmidt, et al.
Archives of Endocrinology and Metabolism|September 3, 2015
Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancerFabián Pitoia, Erika Abelleira, Fernando Jerkovich, et al.
Arquivos Brasileiros De Endocrinologia E Metabologia|June 10, 2011
Patients with familial non-medullary thyroid cancer have an outcome similar to that of patients with sporadic papillary thyroid tumorsFabián Pitoia, Graciela Cross, María E Salvai, et al.
European Thyroid Journal|August 9, 2017
Should Age at Diagnosis Be Included as an Additional Variable in the Risk of Recurrence Classification System in Patients with Differentiated Thyroid CancerFabián Pitoia, Fernando Jerkovich, Anabella Smulever, et al.
Thyroid : Official Journal of the American Thyroid Association|March 23, 2013
Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systemsFabián Pitoia, Fernanda Bueno, Carolina Urciuoli, et al.
Medicina|May 27, 2008
Sex hormone binding globulin decrease as a potential pathogenetic factor for hirsutism in adolescent girlsGraciela Cross, Karina Danilowicz, Martha Kral, et al.
Medicina|October 28, 2014
[Female hyperandrogenemia and normal serum levels of testosterone and sex hormone binding globulin]Karina Danilowicz, Oscar D Bruno, Daniela Mana, et al.
Pageof 2